Biofourmis plans to expand its footprint in the United States by relocating its headquarters from Singapore to Boston and growing its Boston office.

Investors include Sequoia Capital India, MassMutual Ventures, and participation from Singapore's Economic Development Board, Openspace Ventures, and Aviva Ventures.

Biofourmis Singapore Pte Ltd closed a $35 million Series B round to support its growth.

The funding will be used to bolster operations and accelerate expansion across the U.S. and Asian markets, while strengthening core teams.

The co-founder and CEO notes that the latest investment will validate Biofourmis' therapeutics platform and drive improvements in patient care and health outcomes.

Anjana Sasidharan of Sequoia Capital India expressed confidence in Biofourmis’ offerings and noted the shift of digital therapeutics from concept to practical reality.